Etiologic role of lactic dehydrogenase virus infection in an age-dependent neuroparalytic disease in C58 mice

Lactic dehydrogenase virus (LDV) associated with transplantable line Ib lymphocytic leukemia in C58/Wm mice, K36 lymphocytic leukemia in AKR/J mice, and the Gardner lymphosarcoma in C3H/HeJ mice elicited a fatal neuroparalytic disease when injected ip into 7- to 9-month-old X-irradiated indicator C58 mice. LDV associated with the WEHI-3B line of transplantable myelomonocytic leukemia or the Harding-Passey transplantable myeloma in BALB/c mice failed to elicit the disease. Recipients of such tumor extracts were immune to rechallenge by line Ib-associated LDV. Tumor lines free of LDV failed to elicit the disease or immunize recipient mice to line Ib LDV challenge. The Plagemann (P-LDV), Riley (R-LDV), and Notkins (N-LDV) strains of LDV were less neuropathogenic than the line Ib-derived strain (Ib-LDV). Indicator C58 mice that survived infection by the P-LDV, R-LDV, and N-LDV strains were immune to rechallenge by Ib-LDV. Antiserum prepared in young C58 mice to Ib-LDV or R-LDV protected indicator C58 mice from Ib-LDV challenge. These results show that a common viral contaminant of transplantable tumors and virus stocks that ordinarily is not pathogenic elicits a fatal neurologic disease in genetically susceptible, immunosuppressed, C58 mice.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/23254/1/0000187.pd

FV-1 restriction of age-dependent paralytic lactic dehydrogenase virus infection

A genetic analysis was made of the susceptibility of inbred mice to a paralytic disease elicited by the ip injection of a neuroparalytic strain of lactic dehydrogenase virus. The frequency of disease in susceptible inbred mice was X-ray dose and age dependent. Analysis of the susceptibility of appropriate F1 hybrids and their backcross progeny showed that susceptibility was not linked to the major histocompatibility complex but segregated with the Fv-1 linkage group. Linkage group analysis showed that resistance to paralytic infection was linked to a single gene outside the major histocompatibility complex. By determining the segregation of Gpd-1 isozyme variants among backcross progeny it was shown that inheritance of the Fv-1b allele resulted in virtually absolute restriction of susceptibility. Genetic evidence was obtained indicating that mice that mice that had multiple copies of N-tropic C-type retroviruses in their genomes, and that were permissive for retrovirus expression (Fv-1n/n), were susceptible to paralytic LDV infection. Strains that carried few copies of N-tropic C-type retroviruses in their genomes, or that inherited the Fv-1b allele, were resistant. A significant maternal resistance effect was demonstrable in some backcross generations that appeared to be mediated by H-2b in the major histocompatibility complex.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/24060/1/0000312.pd

A Single Dose of Neuron-Binding Human Monoclonal Antibody Improves Spontaneous Activity in a Murine Model of Demyelination

Our laboratory demonstrated that a natural human serum antibody, sHIgM12, binds to neurons in vitro and promotes neurite outgrowth. We generated a recombinant form, rHIgM12, with identical properties. Intracerebral infection with Theiler's Murine Encephalomyelitis Virus (TMEV) of susceptible mouse strains results in chronic demyelinating disease with progressive axonal loss and neurologic dysfunction similar to progressive forms of multiple sclerosis. To study the effects of rHIgM12 on the motor function of TMEV-infected mice, we monitored spontaneous nocturnal activity over many weeks. Nocturnal behavior is a sensitive measure of rodent neurologic function because maximal activity changes are expected to occur during the normally active night time monitoring period. Mice were placed in activity boxes eight days prior to treatment to collect baseline spontaneous activity. After treatment, activity in each group was continuously recorded over 8 weeks. We chose a long 8-week monitoring period for two reasons: (1) we previously demonstrated that IgM induced remyelination is present by 5 weeks post treatment, and (2) TMEV-induced demyelinating disease in this strain progresses very slowly. Due to the long observation periods and large data sets, differences among treatment groups may be difficult to appreciate studying the original unfiltered recordings. To clearly delineate changes in the highly fluctuating original data we applied three different methods: (1) binning, (2) application of Gaussian low-pass filters (GF) and (3) polynomial fitting. Using each of the three methods we showed that compared to control IgM and saline, early treatment with rHIgM12 induced improvement in both horizontal and vertical motor function, whereas later treatment improved only horizontal activity. rHIgM12 did not alter activity of normal, uninfected mice. This study supports the hypothesis that treatment with a neuron-binding IgM not only protects neurons in vitro, but also influences functional motor improvement

Indirect Recruitment of a CD40 Signaling Pathway in Dendritic Cells by B7-DC Cross-Linking Antibody Modulates T Cell Functions

The human IgM B7-DC XAb protects mice from tumors in both therapeutic and prophylactic settings. Its mechanism of action is mediated by its binding to B7-DC/PD-L2 molecules on the surface of dendritic cells (DCs) to induce a multimolecular cap and subsequent activation of signaling cascades that determine a unique combination of DC phenotypes. One such phenotype, the B7-DC XAb-induced antigen accumulation in mTLR-matured DCs, has been linked to signaling through TREM-2, but the signals required for other DC phenotypes critical for the therapeutic effects in animal models remain unclear. Here, FRET and co-immunoprecipitation studies show that CD40 is recruited to the multi-molecular complex by B7-DC XAb. Signals emanating from CD40 are important, as CD40−/− DCs treated with B7-DC XAb (DCXAb) activated DAP12, but failed to activate NFκB, and were not protected from cell death upon cytokine withdrawal or treatment with Vitamin D3. CD40−/− DCXAb also failed to secrete IL-6 and were unable to support the conversion of T regulatory cells into IL-17+ effector T cells in vitro. Importantly, the expression of CD40 was required for the overall ability of B7-DC XAb to induce anti-tumor CTL, to provide protection from a number of tumor types, and for DCXAb to be effective anti-tumor vaccines in vivo. These results indicate that B7-DC XAb modulation of DC phenotypes is through its ability to indirectly recruit common signaling molecules and elements of their endogenous signaling pathways through targeted binding to a cell-specific surface determinant

Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells

B7-DC molecules are known to function as ligands on antigen-presenting cells (APCs), enhancing T cell activation. In this study, cross-linking B7-DC with the monoclonal antibody sHIgM12 directly potentiates dendritic cell (DC) function by enhancing DC presentation of major histocompatibility complex–peptide complexes, promoting DC survival; and increasing secretion of interleukin (IL)-12p70, a key T helper cell type 1 promoting cytokine. Furthermore, ex vivo treatment of DCs or systemic treatment of mice with sHIgM12 increases the number of transplanted DCs that reach draining lymph nodes and increases the ability of lymph node APCs to activate naive T cells. Systemic administration of the antibody has an equivalent effect on DCs transferred at a distant site. These findings implicate B7-DC expressed on DCs in bidirectional communication. In addition to the established costimulatory and inhibitory functions associated with B7-DC, this molecule can also function as a conduit for extracellular signals to DCs modifying DC functions

Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses

Head-to-head comparisons of conventional influenza vaccines with ade- novirus (Ad) gene-based vaccines demonstrated that these viral vectors can mediate more potent protection against influenza virus infection in animal models. In most cases, Ad vaccines are engineered to be replication-defective (RD-Ad) vectors. In contrast, replication-competent Ad (RC-Ad) vaccines are markedly more potent but risk causing adenovirus diseases in vaccine recipients and health care workers. To harness antigen gene replication but avoid production of infectious virions, we de- veloped “single-cycle” adenovirus (SC-Ad) vectors. Previous work demonstrated that SC-Ads amplify transgene expression 100-fold and produce markedly stronger and more persistent immune responses than RD-Ad vectors in Syrian hamsters and rhe- sus macaques. To test them as potential vaccines, we engineered RD and SC ver- sions of adenovirus serotype 6 (Ad6) to express the hemagglutinin (HA) gene from influenza A/PR/8/34 virus. We show here that it takes approximately 33 times less SC-Ad6 than RD-Ad6 to produce equal amounts of HA antigen in vitro. SC-Ad pro- duced markedly higher HA binding and hemagglutination inhibition (HAI) titers than RD-Ad in Syrian hamsters. SC-Ad-vaccinated cotton rats had markedly lower influ- enza titers than RD-Ad-vaccinated animals after challenge with influenza A/PR/8/34 virus. These data suggest that SC-Ads may be more potent vaccine platforms than conventional RD-Ad vectors and may have utility as “needle-free” mucosal vaccines

Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses

Head-to-head comparisons of conventional influenza vaccines with adenovirus (Ad) gene-based vaccines demonstrated that these viral vectors can mediate more potent protection against influenza virus infection in animal models. In most cases, Ad vaccines are engineered to be replication-defective (RD-Ad) vectors. In contrast, replication-competent Ad (RC-Ad) vaccines are markedly more potent but risk causing adenovirus diseases in vaccine recipients and health care workers. To harness antigen gene replication but avoid production of infectious virions, we developed “single-cycle” adenovirus (SC-Ad) vectors. Previous work demonstrated that SC-Ads amplify transgene expression 100-fold and produce markedly stronger and more persistent immune responses than RD-Ad vectors in Syrian hamsters and rhesus macaques. To test them as potential vaccines, we engineered RD and SC versions of adenovirus serotype 6 (Ad6) to express the hemagglutinin (HA) gene from influenza A/PR/8/34 virus. We show here that it takes approximately 33 times less SC-Ad6 than RD-Ad6 to produce equal amounts of HA antigen in vitro. SC-Ad produced markedly higher HA binding and hemagglutination inhibition (HAI) titers than RD-Ad in Syrian hamsters. SC-Ad-vaccinated cotton rats had markedly lower influenza titers than RD-Ad-vaccinated animals after challenge with influenza A/PR/8/34 virus. These data suggest that SC-Ads may be more potent vaccine platforms than conventional RD-Ad vectors and may have utility as “needle-free” mucosal vaccines